# ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

> **NCT03287271** · PHASE1,PHASE2 · RECRUITING · sponsor: **Michael McHale** · enrollment: 90 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** VS-6063
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03287271
- **Lead sponsor:** Michael McHale
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-02-06
- **Primary completion:** 2025-04
- **Final completion:** 2026-04
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-08-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03287271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03287271, "ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03287271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*